Current Neuro-Oncology
Volume
26 Number 2
31 January 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 2, 31 January
Drexler R, Brembach F, Sauvigny J,
Ricklefs FL, Eckhardt A, Bode H, Gempt J, Lamszus K, Westphal M,
Schüller U, Mohme M.
Unclassifiable
CNS tumors in DNA methylation-based classification: clinical
challenges and prognostic impact.
Acta
Neuropathol Commun.
2024 Jan 16;12(1):9. doi:
10.1186/s40478-024-01728-9. PMID:
38229158. Observational study. ˍ
Rynda AY, Rostovthev DM,
Zabrodskaya YM, Olyushin VE.
Immunotherapy
with autologous
dendritic cells in the complex treatment of malignant gliomas –
results.
J
Neurooncol. 2024
Jan 16;166(2):309-319. doi:
10.1007/s11060-023-04559-1. PMID:
38227144. Observational
study˰ ˍ
Zhao B, Yao J, Wang J, Li J, Shi W,
Zhang C, Zhao X, Qiao J, Ma Y, Xu Y, Zheng Z.
Usefulness
of magnetic resonance imaging characteristics in discriminating H3
K27M-mutant gliomas from wildtype gliomas in spinal cord.
Neurol
Sci. 2024 Jan 16.
doi:
10.1007/s10072-024-07315-z. PMID:
38228940. Observational study˰ ˍ
*Ainslie AP, Klaver M, Voshart DC,
Gerrits E, den Dunnen WFA, Eggen BJL, Bergink S, Barazzuol
L.
Glioblastoma
and its treatment are associated with extensive accelerated brain
aging.
Aging
Cell. 2024 Jan
17:e14066. doi:
10.1111/acel.14066. PMID:
38234228. Observational study. ˍ
Carlson MA, Fradgley EA, Paul CL.
Understanding
experiences of cognitive decline and cognitive assessment from the
perspectives of people with glioma and their caregivers: A
qualitative interview study.
Int
J Nurs Stud Adv. 2024 Jan 17;6:100179. doi:
10.1016/j.ijnsa.2024.100179. PMID:
38746812. Observational study. ˍ
Chaban A, Waschulzik B, Bernhardt
D, Delbridge C, Schmidt-Graf F, Wagner A, Wiestler B, Weber W,
Yakushev I.
Amino
acid PET vs. RANO MRI for prediction of overall survival in
patients with recurrent high grade glioma under bevacizumab
therapy.
Eur
J Nucl Med Mol Imaging.
2024 Jan 17. doi:
10.1007/s00259-024-06601-4. PMID:
38228970. Observational study. ˍ
Fariña-Jerónimo H,
Martín-Ramírez R, González-Fernández
R, Medina L, de Vera A, Martín-Vasallo P, Plata-Bello
J.
Androgen
deficiency is associated with a better prognosis in
glioblastoma.
Eur
J Med Res. 2024
Jan 17;29(1):57. doi:
10.1186/s40001-024-01648-3. PMID:
38233838. Observational study. ˍ
Krystal J, Hanson D, Donnelly D,
Atlas M.
A
phase 1 study of mebendazole with bevacizumab and irinotecan in
high-grade gliomas.
Pediatr
Blood Cancer.
2024 Jan 17:e30874. doi:
10.1002/pbc.30874. PMID:
38234020. Interventional
study˰
ˍ
Marastoni E, Ammendola S, Rossi S,
Giovannoni I, Broggi G, Masotto B, Feletti A, Barresi V.
H3
K27M mutation in rosette-forming glioneuronal tumors: a potential
diagnostic pitfall.
Virchows
Arch. 2024 Jan
17. doi:
10.1007/s00428-024-03739-2. PMID:
38233563. Observational study. ˍ
*Beckham
TH, Rooney MK, McAleer MF, Ghia AJ, Tom MC, Perni S, McGovern S,
Grosshans D, Chung C, Wang C, De B, Swanson T, Paulino A, Jiang W,
Ferguson S, Patel CB, Li J, Yeboa DN.
Hypofractionated
radiotherapy for glioblastoma: A large institutional retrospective
assessment of 2 approaches.
Neurooncol
Pract.
2024 Jan 18;11(3):266-274. doi:
10.1093/nop/npae004. PMID:
38737610. Observational study˰ ˍ
Goldlust SA, Nabors LB, Hsu S, Mohile N, Duic PJ, Benkers T,
Singer S, Rao M, Cappello L, Silberman SL, Farmer G.
Phase
1 trial of TPI 287, a microtubule stabilizing agent, in
combination with bevacizumab in adults with recurrent
glioblastoma.
Neurooncol
Adv. 2024 Jan 18;6(1):vdae009. doi:
10.1093/noajnl/vdae009. PMID:
38327681. Interventional study. ˍ
Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, Grishanina
NR, Kwok D, Stevers NO, Jin Q, Youngblood MW, Stasiak LA, Hou Y,
Wang J, Yamaguchi TN, Lafontaine M, Shai A, Smirnov IV, Solomon
DA, Chang SM, Hervey-Jumper SL, Berger MS, Lupo JM, Okada H,
Phillips JJ, Boutros PC, Gallo M, Oldham MC, Yue F, Costello
JF.
Glioblastoma evolution and
heterogeneity from a 3D whole-tumor perspective.
Cell.
2024 Jan 18;187(2):446-463.e16. doi:
10.1016/j.cell.2023.12.013. PMID:
38242087. Laboratory investigation.
ˍ
Related
article:
Baig S, Winkler
F.
A
holistic view of the malignant organism we call
glioblastoma.
Cell.
2024 Jan 18;187(2):271-273. doi:
10.1016/j.cell.2023.12.021. PMID:
38242083. Comment˰ ˍ
Heymer EJ, Hawkins MM, Winter DL,
Teepen JC, Sunguc C, Ronckers CM, Allodji RS, Alessi D, Sugden E,
Belle FN, Bagnasco F, Byrne J, Bárdi E, Garwicz S, Grabow
D, Jankovic M, Kaatsch P, Kaiser M, Michel G, Schindera C, Haddy
N, Journy N, Česen Mazić M, Skinner R, Kok JL, Gunnes
MW, Wiebe T, Sacerdote C, Maule MM, Terenziani M, Jakab Z, Winther
JF, Lähteenmäki PM, Zadravec Zaletel L, Haupt R, Kuehni
CE, Kremer LC, de Vathaire F, Hjorth L, Reulen RC.
Risk
of subsequent gliomas and meningiomas among 69,460 5-year
survivors of childhood and adolescent cancer in Europe: the
PanCareSurFup study.
Br
J Cancer. 2024
Jan 19. doi:
10.1038/s41416-024-02577-y. PMID:
38243010. Observational study. ˍ
Orimoloye HT, Nguyen N,
Deng C, Saechao C, Ritz B, Olsen J, Hansen J, Heck JE.
Maternal
autoimmune disease and its association with childhood cancer: A
population-based case-control study in Denmark.
EJC
Paediatr Oncol.
2024 Jan 19;3:100145. doi:
10.1016/j.ejcped.2024.100145. PMID:
38298419. Observational study. ˍ
*Karatsu K, Tamura R, Yo M, Nogawa
H, Hino U, Kitamura Y, Ueda R, Toda M.
The
Role of Genetic Analysis in Distinguishing Multifocal and
Multicentric Glioblastomas: An Illustrative Case.
Case
Rep Oncol. 2024
Jan 22;17(1):113-121. doi:
10.1159/000536051. PMID:
38260034. Case report. ˍ
Pepper NB, Eich HT, Müther M,
Oertel M, Rehn S, Spille DC, Stummer W.
ALA-RDT
in GBM: protocol of the phase I/II dose escalation trial of
radiodynamic therapy with 5-Aminolevulinic acid in patients with
recurrent glioblastoma.
Radiat
Oncol. 2024 Jan
22;19(1):11. doi:
10.1186/s13014-024-02408-7. PMID:
38254201. Interventional
study protocol. ˍ
Fadul CE, Thakur A, Kim J, Kassay-McAllister J, Schalk D, Lopes
MB, Donahue J, Purow B, Dillon P, Le T, Schiff D, Liu Q, Lum
LG.
Phase I study targeting newly
diagnosed grade 4 astrocytoma with bispecific antibody armed T
cells (EGFR BATs) in combination with radiation and
temozolomide.
J
Neurooncol. 2024 Jan 23;166(2):321-330. doi:
10.1007/s11060-024-04564-y. PMID:
38263486. Interventional
study. ˍ
Tang T, Wang Y, Dai Y, Liu Q, Fan
X, Cheng Y, Tang J, Xiao X, Shan Y, Wei P, Zhao G.
IDH1
mutation predicts seizure occurrence and prognosis in lower-grade
glioma adults.
Pathol
Res Pract. 2024
Jan 24;254:155165. doi:
10.1016/j.prp.2024.155165. PMID:
38286053. Observational study˰ ˍ
Dar MS, Shahid N, Waqas A, Baig YA,
Khan AW.
Dabrafenib
plus Trametinib: A breakthrough in pediatric low-grade glioma
therapy.
Health
Sci Rep. 2024 Jan
25;7(1):e1841. doi:
10.1002/hsr2.1841. PMID:
38274133. Interventional
study. ˍ
Liao Y, Bai X, Cao Y, Zhang
M.
Effect
of low-dose bevacizumab on health-related quality of life in
patients with recurrent high-grade glioma: A retrospective
clinical study.
J
Clin Neurosci.
2024 Jan 25;120:196-203. doi: 10.1016/j.jocn.2024.01.018? PMID:
38277995. Observational study. ˍ
Lu Y, Liao L, Du K, Mo J, Zou X, Liang J, Chen J, Tang W, Su L, Wu
J, Zhang J, Tan Y.
Clinical activity
and safety of sintilimab, bevacizumab, and TMZ in patients with
recurrent glioblastoma.
BMC
Cancer. 2024 Jan 25;24(1):133. doi:
10.1186/s12885-024-11848-z. PMID:
38273249. Observational study. ˍ
Hammoud M, Hmamouche OM, Lakhdar F, Benzagmout M, Chakour K,
Chaoui MEF.
Pediatric extra-axial
glioblastoma with bone invasion leading to a subcutaneous mass: A
case report.
Surg
Neurol Int. 2024 Jan 26;15:25. doi:
10.25259/SNI_809_2023. PMID:
38344102. Case report. ˍ
Heuer S, Burghaus I, Gose M,
Kessler T, Sahm F, Vollmuth P, Venkataramani V, Hoffmann D,
Schlesner M, Ratliff M, Hopf C, Herrlinger U, Ricklefs F, Bendszus
M, Krieg SM, Wick A, Wick W, Winkler F.
PerSurge
(NOA-30) phase II trial of perampanel treatment around surgery in
patients with progressive glioblastoma.
BMC
Cancer. 2024 Jan
26;24(1):135. doi:
10.1186/s12885-024-11846-1. PMID:
38279087. Interventional
study protocol. ˍ
Shields LB, O'Dell P, Daniels MW, Sevak PR, Highfield HA,
Sinicrope KD, Sun DA, Spalding AC.
Impact
of Reirradiation Utilizing Fractionated Stereotactic Radiotherapy
for Recurrent Glioblastoma.
Cureus.
2024 Jan 26;16(1):e53001. doi:
10.7759/cureus.53001. PMID:
38406061. Observational study. ˍ
Kameda-Smith MM, Ragulojan M,
Elliott C, Bliss L, Moore H, Sader N, Alsuwaihel M, Tso MK, Dakson
A, Ajani O, Yarascavitch B, Fleming A, Mehta V, Aminnejad M,
Farrokhyar F, Singh SK; McMaster Pediatric Brain Tumour Study
Group (PBTSG) and the Canadian Neurosurgery Research Collaborative
(CNRC).
National
multicentered retrospective review of clinical and intraoperative
factors associated with the development of cerebellar mutism after
pediatric posterior fossa tumor resection.
Childs
Nerv Syst. 2024
Jan 27. doi:
10.1007/s00381-024-06292-0. PMID:
38279985. Observational study˰ ˍ
Yekula A, Gessler DJ, Ferreira C, Shah R, Reynolds M, Dusenbery K,
Chen CC.
GammaTile®
(GT) as a brachytherapy platform for rapidly proliferating
glioblastomas: from case series to clinical trials.
J
Neurooncol. 2024 Jan 28. doi:
10.1007/s11060-023-04545-7. PMID:
38281303. Observational study˰
ˍ
Fiveash JB, Ye X, Peerboom DM,
Mikkelsen T, Chowdhary S, Rosenfeld M, Lesser GJ,
Fisher J, Desideri S, Grossman S, Leopold L, Nabors LB.
Clinical
trials of R-(-)-gossypol
(AT-101) in newly diagnosed and recurrent glioblastoma: NABTT
0602
and NABTT 0702.
PLoS
One. 2024 Jan
29;19(1):e0291128. doi:
10.1371/journal.pone.0291128. PMID:
38285688. Interventional
study. ˍ
Rimmer B, Balla M, Dutton L, Williams S, Lewis J, Gallagher P,
Finch T, Burns R, Araújo-Soares V, Menger F, Sharp L; Ways
Ahead Study Team.
"It changes
everything": Understanding how people experience the impact
of living with a lower-grade glioma.
Neurooncol
Pract. 2024 Jan 29;11(3):255-265. doi:
10.1093/nop/npae006. PMID:
38737616. Observational
study. ˍ
*Rossmeisl JH, King JN, Robertson JL, Weger-Lucarelli J,
Elankumaran S.
Phase I/II Trial of
Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle
Disease Virus for Canine Intracranial Tumors.
Cancers
(Basel). 2024 Jan 29;16(3):564. doi:
10.3390/cancers16030564. PMID:
38339315. Interventional animal study. ˍ
Shenoy G, Slagle-Webb B,
Khunsriraksakul C, Pandya Shesh B, Luo J, Khristov V, Smith N,
Mansouri A, Zacharia BE, Holder S, Lathia JD, Barnholtz-Sloan JS,
Connor JR.
Analysis
of anemia and iron supplementation among glioblastoma patients
reveals sex-biased association between anemia and survival.
Sci
Rep. 2024 Jan
29;14(1):2389. doi:
10.1038/s41598-024-52492-8. PMID:
38287054. Observational study. ˍ
*Hao Z, Wang J, Lv Y, Wu W,
Zhang S, Hao S, Chu J, Wan H, Feng J, Ji N.
Identification
of MGMT promoter methylation as a specific lipid metabolism
biomarker, reveals the feasibility of atorvastatin application in
glioblastoma.
Metabolism.
2024 Jan 30;153:155794. doi:
10.1016/j.metabol.2024.155794. PMID:
38301843. Laboratory investigation˰
ˍ
van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA,
Cruz-Martínez O, Zápotocký M, Scheinemann K,
Meeteren AYNS, Sehested A, Opocher E, Driever PH, Avula S, Ziegler
DS, Capper D, Koch A, Sahm F, Qiu J, Tsao LP, Blackman SC, Manley
P, Milde T, Witt R, Jones DTW, Hargrave D, Witt
O.
LOGGIC/FIREFLY-2: a phase 3,
randomized trial of tovorafenib vs. chemotherapy in pediatric and
young adult patients with newly diagnosed low-grade glioma
harboring an activating RAF alteration.
BMC
Cancer. 2024 Jan 30;24(1):147. doi:
10.1186/s12885-024-11820-x. PMID:
38291372. Interventional
study
protocol.
ˍ
Habashy KJ, Dmello C, Chen L, Arrieta VA, Kim KS, Gould A,
Youngblood MW, Bouchoux G, Bell Burdett KB, Zhang H, Canney M,
Stupp R, Sonabend AM.
Paclitaxel and
Carboplatin in Combination with Low-Intensity Pulsed Ultrasound
for Glioblastoma.
Clin
Cancer Res. 2024 Jan 31. doi:
10.1158/1078-0432.CCR-23-2367. PMID:
38295144. Observational study˰
ˍ
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto
Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama
Y, Miyake K, Sasaki H.
An exploratory
prospective phase II study of preoperative neoadjuvant bevacizumab
and temozolomide for newly diagnosed glioblastoma.
J
Neurooncol. 2024 Jan 31. doi:
10.1007/s11060-023-04544-8. PMID:
38291182. Interventional
study. ˍ
Yilmaz MT, Kahvecioglu A, Yedekci FY, Yigit E, Ciftci GC, Kertmen
N, Zorlu F, Yazici G.
Comparison of
different target volume delineation strategies based on recurrence
patterns in adjuvant radiotherapy for glioblastoma.
Neurooncol
Pract. 2024 Jan 31;11(3):275-283. doi:
10.1093/nop/npae009. PMID:
38737611. Observational
study. ˍ